Advanced in Virilizing Ovarian Tumor

Dr. Zoneddy R. Dayao

Hematology Oncology | Hematology | Oncology
Unm Medical Group Inc
2211 Lomas Blvd Ne, 
Albuquerque, NM 
Advanced in Virilizing Ovarian Tumor
Unm Medical Group Inc
2211 Lomas Blvd Ne, 
Albuquerque, NM 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Zoneddy Dayao is a Hematologist Oncology specialist and a Hematologist in Albuquerque, New Mexico. Dr. Dayao is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Angiosarcoma.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NM
Hospital Affiliations
Unm Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

UNM MEDICAL GROUP INC
2211 Lomas Blvd Ne, Albuquerque, NM 87106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other
Study Phase: Not Applicable
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome
A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome
Enrollment Status: Completed
Publish Date: October 05, 2022
Intervention Type: Dietary supplement, Drug
Study Phase: Not Applicable
View 5 Less Clinical Trials

26 Total Publications

Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 27, 2025
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Karen A. Finkelstein
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Karen A. Finkelstein
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Southwest Women's Oncology Inc

2400 Unser Blvd Se, Suite 28300, 
Albuquerque, NM 
 (10.0 miles away)
505-843-7813
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Karen Finkelstein is a Gynecologic Oncologist and an Oncologist in Albuquerque, New Mexico. Dr. Finkelstein is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hernia Surgery. Dr. Finkelstein is currently accepting new patients.

Advanced in Virilizing Ovarian Tumor
Dr. Ethan Binder
Hematology Oncology | Hematology | Oncology
Advanced in Virilizing Ovarian Tumor
Dr. Ethan Binder
Hematology Oncology | Hematology | Oncology

Presbyterian Healthcare Services

2400 Unser Blvd Se, 
Rio Rancho, NM 
 (10.0 miles away)
505-253-7878
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Ethan Binder is a Hematologist Oncology specialist and a Hematologist in Rio Rancho, New Mexico. Dr. Binder is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Choriocarcinoma, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Breast Cancer.

Distinguished in Virilizing Ovarian Tumor
Dr. Sara M. Jordan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Sara M. Jordan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Presbyterian Healthcare Services

1100 Central Ave Se, 
Albuquerque, NM 
 (1.0 miles away)
505-841-1234
Languages Spoken:
English, Arabic, Cantonese, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sara Jordan is a Gynecologic Oncologist and an Oncologist in Albuquerque, New Mexico. Dr. Jordan is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Testicular Yolk Sac Tumor, Oophorectomy, and Hernia Surgery. Dr. Jordan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dayao's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 61 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile